Treatment of premature ovarian insufficiency using autologous bone marrow concentrates through a transvaginal approach under ultrasound guidance: A Case Report premature ovarian insufficiency & autologous bone marrow concentrates
Article Sidebar
Main Article Content
Abstract
Premature ovarian insufficiency (POI) is a clinical syndrome characterized by an early loss of ovarian function, manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotrophin hormones and low levels of estrogen and anti-Mullerian hormones. Regenerative medicine treats a variety of diseases by using cells or biological products instead of conventional drugs or other interventions. The autologous use of stem cells from bone marrow or adipose tissue (stromal vascular fraction) or growth factor products such as platelet-rich plasma are safe alternative minimally manipulated products that can potentially solve this clinical problem without an oocyte donation program. The current study reports the application of regenerative medicine: autologous bone marrow aspirate concentrate is used to treat premature ovarian insufficiency using minimal manipulation combined with minimal surgical intervention through an intravaginal approach under ultrasound guidance. In conclusion, to the authors' knowledge, this is the first case study that reports the treatment of ROI via a transvaginal approach in delivering bone marrow aspirate concentrate.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/
References
1. Fenton, Anna J. "Premature ovarian insufficiency: Pathogenesis and management." Journal of mid-life health 6.4 (2015): 147.
2. Ishizuka, Bunpei. "Current understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI)." Frontiers in endocrinology 12 (2021): 626924.
3. Sheikhansari, Golshan, et al. "Current approaches for the treatment of premature ovarian failure with stem cell therapy." Biomedicine & pharmacotherapy 102 (2018): 254-262.
4. Huang Y, Zhu M, Liu Z, Hu R, Li F, Song Y, Geng Y, Ma W, Song K and Zhang M (2022) Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects. Front. Immunol. 13:997808. doi: 10.3389/fimmu.2022.997808
5. Zhang, Cheng. "The roles of different stem cells in premature ovarian failure." Current stem cell research & therapy 15.6 (2020): 473-481.
6. Edessy M, et al. Autologous stem cells therapy, the first baby of idiopathic premature ovarian failure. Acta Medica International. 2016;3(1):19–23. doi: 10.5530/ami.2016.1.7.
7. Elkheir EAH. Autologous stem cell transplantation in patients with idiopathic premature ovarian failure. J Tissue Sci Eng. 10.4172/2157-7552.C1.030.